Cindy is passionate about innovation to make genetic and multi-omic technologies easier and cheaper to measure. She sees such innovation as pivotal to lower the barrier of entry for implementing scalable, reproducible solutions advancing individualized medicine and health equity. In over 14 years at Illumina, she helped develop genetic and genomic based solutions to advance the understanding of genetic risk and holds several awards for her genetic work for Excellence in Technology Transfer. She joined Olink soon after the launch of the Explore Platform that leverages next generation sequencing as a high throughput proteomic readout to measure ~3,000 proteins in just 6uL of sample. Ask her about how high throughput proteomics are helping translate the impact our genetics has on more real time health.
Framework for Target Discovery toward Multi-omic Supported Precision Medicine
Massive advances in genetic discoveries over the past decade are due in large part to the drastic drop in sequencing pricing and increased availability of academic-, industry- and government- affiliated large cohorts and biobanks. Advances in proteomics are now enabling us to translate the impact our genetics has on more real-time health.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.